biologic

Hepagam B

Hepatitis B Immune Globulin (Human)

Loss of exclusivityJanuary 2018projected — 12-year biologic exclusivity estimate
CompanyKamada Ltd.See this company's full patent-cliff portfolio

Drug detail

Brand nameHepagam B
Active ingredientHepatitis B Immune Globulin (Human)
Strength>1560IU/5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJanuary 2006
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Hepagam B patent cliff — loss of exclusivity January 2018 | CliffBio